Disclosures of: Emanuele Angelucci
|
|
- Alexia Cobb
- 6 years ago
- Views:
Transcription
1 Company name Novartis Disclosures of: Emanuele Angelucci Research support Employee Consultant Stockholder Speakers bureau Advisory board Chair of TELESTO pro Other
2 EBMT 2012 Educational Session Haemoglobinopathy and HSCT Thalassemia
3 Treatment options for Thalassemia Major 1. Transfusions and iron chelation 2. Transplantation 3. Gene Therapy 3
4 Survival Probability Kaplan-Meier survival curves, after the first decade of life by birth cohort Log-rank test: p< Age (years) Borgna 2010
5 Clinical Trial: Gene Transfer of the b 87 lenti-vector into a Hb E-b-thalassemia patient promotes transfusion independence Cavazzana-Calvo,Nature2010
6 Thalassemia epidemiology >330,000 new born with hemoglobinopathy every year 17% Thalassemia (> new born/year) Modell B et al. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86:480-7.
7 HSCT in Thalassemia
8 First HSC transplants for thalassemia Dec 2 nd 1981 in Seattle Dec 17 th 1981 in Pesaro
9 Results of HSCT in 900 consecutive patients, aged 1-35 years, transplanted from an HLA identical sibling in Pesaro since December 1981 Haematologica 2008;93:
10 Probability Results of HSCT in 115 consecutive patients, aged 1-28 years, transplanted from an HLA identical sibling in Pescara since May OS (89.2%) 0.8 DFS (85.7%) Median follow-up 15 years (1-24) n patients at risk (OS) n patients at risk (DFS) Years from BMT Am J Hematol 2008;83:
11 Outcome prediction (HLA identical sibling HSCT)
12 Pesaro risk classification Three risk factors stratified pediatric patients in 3 risk groups N Engl J Med 1990; 322: N Engl J Med 1993; 329: Chelation Hepatomegaly Liver fibrosis No risk factor Low risk 1-2 risk factors Intermediate risk 3 risk factors High risk
13 Pesaro risk classification Three risk factors stratified pediatric patients in 3 risk groups N Engl J Med 1990; 322: N Engl J Med 1993; 329: Chelation Hepatomegaly Liver fibrosis Iron overload. Iron related tissue damage. Classification not applicable to adults patients ( 17 years) Blood Feb 15;93(4):1164-7
14 Pesaro results RISK REGIMEN OS % TFS % TRM % LOW Bu 14 Cy INT Bu 14 Cy HIGH (<1990) Bu 14 Cy HIGH (>1990) Bu 14 Cy ADULT Bu 14 Cy Optimal medical therapy is the key for a successful transplant 2. High risk patients had high TRM with standard Bu-Cy 3. Reducing conditioning regimen intensity (Cy dose) decreased TRM but amplified risk of thalassemia recurrence 4. Adult patients had a high TRM and limited risk of thalassemia recurrence Efficacy of hematopoietic cell transplantation in beta thalassemia In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, Ann N Y Acad Sci 2010; 1202:141-8.
15 Recent preparative regimens Regimen Patients ref iv targeted busulfan + Cy 200 ± thiotepa Lower risks Blood 2010;115: Biol Blood Marrow Transplant 2010;16: Pre-conditioning treatment with hypertransfusion and chelation + hydroxyurea, azathioprinine and fludarabine. Preconditioning treatment with hypertransfusion and chelation + hydroxyurea, azathioprinine and fludarabine. + targeted iv busulfan + Cy 160 High risk Blood 2004; 104: High risk Blood 2010;115: ) Biol Blood Marrow Transplant 2010;16: Thiotepa treosulfan fludarabine all Ann N Y Acad Sci 2010; 1202: Busulfan (iv busulfan) / fludarabine all Bone Marrow Transplant 2007; 40: Preconditioning treatment with hypertransfusion and chelation, hydroxyurea, azathioprinine and fludarabine. Iv targeted busulfan + Cy 90 Adult Ann N Y Acad Sci 2005; 1054: Introduction of new drugs 2. Intensity reduction in high risk and adult patients
16 Recent results RISK OS % TFS % TRM % LOWER HIGH RISK OS% TFS% TRM% ADULT Basic concept from Pesaro experience were confirmed 2. Results improved in all patients categories 3. Reducing conditioning regimen intensity in high risk patients decreased TRM but risk of thalassemia recurrence remains relevant. 4. Adult patients still have a high TRM
17 Research developments
18 Research developments Alternative source of stem cell Peripheral blood Cord blood Alternative donors Matched unrelated Mismatched related Unrelated cord blood
19 Probability MUD transplant in thalassemia. GITMO study 132 patients. Median age 14 (1-35) Overall survival = 85,5% Thalassaemia-free survival = 77,4% Mortality = 14,5% COMPATIBILITY: complete identity high resolution HLA typing for class I (A, B, C) and class II (DrB1, DqB1, DpB1). Rejection = 10,7% Months after transplantation Courtesy by Franco Locatelli GITMO study. N. Y. Acad. Sci. 2005
20 Mismatched related. Haploidentical transplant 22 patients. Median age 7 (range 3-14) Patients (# 22): 2 low risk 6 intermediate risk Outcome (#22) 2 infection related deaths 6 thalassemia recurrences Blood 2010;115:
21 Unrelated cord blood transplant Taiwan Study 1 Retrospective - multicenter EBMT- CIBMTR 2 Patients 32 low risk 51 Median age 5 years 5 years Alive and cured Died na 13 2 years OS na 77% 2 years Thal FS 87% na 1 Biol Blood Marrow Transplant 2010; 16: Bone Marrow Transplant 2010; 45: 378.
22 Is HSCT the worldwide diffuse standard of cure for Thalassemia Major? The EBMT Hemoglobinopathy Registry
23 EBMT Registry 134 Centers, 28 Countries Patients with Haemoglobinopathies N = 3821 Patients transplanted between 1/1/2000 and 12/31/2010 N = 1953 Patients with thalassemia N =1493
24 EBMT Registry : THALASSEMIA Number of identical sibling transplants per Countries 5% 1% 6% 2% 35% Italy 4% 2% 4% 3% 2% France Germany 9% UK 18% Turkey Iran 7% 2% Turkey Iran Netherlands UK Italy Spain Israel Saudi Arabia Greece Jordan Algeria Others
25 EBMT REGISTRY: HSCT and age < 18 yrs > 18yrs
26 Overall Survival HSCT (1493 patients all age groups. Median age = 7 years) in the pair-wise comparison SCT is significantly different to all other grou (unknown/missing not included for evaluation of p-values Patients Events 2-yrs. psu Thalassemia ±0.01
27 Event Free Survival - HSCT (1493 patients all age groups. Median age = 7 years) all 3 pair-wise comparison are significant (Bonferoni) (unknown/missing not included for evaluation of p-values Events: Relapse (=significant worsening)/additional diagnosis or death??? please approve??? Patients Events 2-yrs. pefs Thalassemia ±0.01
28 Thalassemia - Survival and Donor HSCT (1493 patients all age groups. Median age = 7 years) Patients Events 2-yrs. psu p-value MSD ±0.01 <0.001 MFD ±0.04 MUD ±0.04 MMFD ±0.07 MMUD ±0.05
29 Thalassemia - EFS and Donor HSCT (1493 patients all age groups. Median age = 7 years) Patients Events 2-yrs. pefs p-value MSD ±0.01 <0.001 MFD ±0.05. MUD ±0.04. MMFD ±0.08. MMUD ±0.05.
30 Thalassemia Survival and age HSCT (1493 patients) Patients Events 2-yrs. psu p-value < 2 years ±0.03 < years ± years ± years ± years ±0.04. >18 years ±0.04.
31 Thalassemia - EFS and age HSCT (1493 patients) Patients Events 2-yrs. pefs p-value < 2 years ± years ± years ± years ± years ±0.04. >18 years ±0.04.
32 Thalassemia Survival and age Match Sibling Donor (# 1061) Patients Events 2-yrs. psu p-value < 2 years ±0.03 < years ± years ± years ± years ±0.04. >18 years ±0.05.
33 Thalassemia Event Free Survival and age Match Sibling Donor (# 1061) Patients Events 2-yrs. pefs p-value < 2 years ± years ± years ± years ± years ±0.05. >18 years ±0.05
34 The problem of the costs
35 The problem of the costs Medical therapy HSCT Gene therapy Direct costs in Italy (transfusion + chelation with DFO) Acute Leukemia. Euro Study. Median value =14,916 /year = 94,350 (CV 40%) Manipulated stem cell??????? Scalone L et al. Curr Med Res Opin 2008;24: Orsi C et al Bone Marrow Transplant 2007; 40: Personal information
36 SCD as emerging problem of public health in non endemic areas Weatherall DJ et al. Bulletin WHO 79: 704, 2001; Modell B et al Bulletin WHO 86: 480, 2008
37 Conclusions
38 Conclusions - 1 HSCT is a today - worldwide available - high success curative procedure for thalassemia Well defined accepted and experimental approaches HLA identical sibling HSCT HLA well match unrelated donor HSCT HLA identical sibling cord blood HSCT HLA matched unrelated cord blood HSCT HLA mismatch related donor transplant Accepted Accepted Accepted Experimental Experimental ASH Education Book, 2010 vol no
39 Conclusions - 2 Optimal medical therapy is the key for a successful transplant Best results have been reported in young well chelated children HSCT is cost-effective
40 Conclusions - 3 Any new developing, intent to cure, procedure should demonstrate at least its equivalence to HSCT
41 Conclusion 2. Factors that must be considered for individual decision making about HSCT for thalassemia Angelucci, E. Hematology 2010;2010: Copyright 2010 American Society of Hematology. Copyright restrictions may apply.
42 Acknowledgements EBMT PDWP Peters Christina Elarouci Nabila Ruiz Elvira Carmen Baronciani Donatella Cagliari Businco Cancer Centre Hematology group All Hospital colleagues and personal Di Bartolomeo Paolo Locateli Franco Kabbara Nabil
43 Thank you for your attention
COHEM Barcellona 2012 Hemoglobinopathies debate
COHEM Barcellona 2012 Hemoglobinopathies debate September 8, 2012: h. 10:30-12:00 Hall: A Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors? HSCT indication
More informationHaemoglobinophaties EBMT 2011 Data Manager session
Haemoglobinophaties EBMT 2011 Data Manager session Presentation plan Biological characteristics Clinical characteristics Transplant resuts What is different From transplant in malignancies Between Thalassemia
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationStem cell transplantation for haemoglobinopathies. Dr P J Darbyshire Birmingham Childrens Hospital
Stem cell transplantation for haemoglobinopathies Dr P J Darbyshire Birmingham Childrens Hospital Survival by Cohort of Birth (N=977) 1.00 85-97 80-84 75-79 70-74 0.75 Survival Probability 0.50 0.25 P
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationYes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples
4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone
More informationCan All Thalassemia Patients be Cured? Suradej Hongeng, MD Dept of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University
Can All Thalassemia Patients be Cured? Suradej Hongeng, MD Dept of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University Thalassemia α thalassemia disease Hb bart ( / ) Hb H disease
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationArticle Stem cell transplantation for thalassaemia
RBMOnline - Vol 10. No 1. 2005 111-115 Reproductive BioMedicine Online; www.rbmonline.com/article/1525 on web 10 November 2004 Article Stem cell transplantation for thalassaemia Dr Javid Gaziev Javid Gaziev
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More information1 Kattamis et al. Growth of Children with Thalassemia: Effect of Different Transfusion Regimens. Archives of
Objectives Sickle Cell Anemia and Thalassemia: Transplantation Provide overview of hemoglobinopathies: Sickle cell disease and Thalassemia Discuss approaches to therapy Review recent registry collaboration
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationBone Marrow Transplantation When and How?
Bone Marrow Transplantation When and How? Dr. Chirag A. Shah Diplomate American Board of Hematology Diplomate American Board of Medical Oncology Director Department of Hemato-Oncology and Stem Cell Transplant,
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More information4nd Patient and Family Day
4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,
More informationUNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE
UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest
More informationHematopietic Stem Cell Transplantation in Thalassemia and Related Disorders
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES www.mjhid.org ISSN 2035-3006 Review article Hematopietic Stem Cell Transplantation in Thalassemia and Related Disorders Emanuele Angelucci 1,
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationLate effects after HSCT
Late effects after HSCT Yves Chalandon Hematology Division, University Hospital of Geneva (HUG) Switzerland Hôpitaux Universitaires de Genève Company name Disclosures of: Yves Chalandon Research support
More informationHOW CAN WE GET THE BEST OUTCOMES FROM CORD BLOOD STEM CELL TRANSPLANTATION IN SEVERE THALASSEMIC PATIENTS: WHEN DOES THE CELL NUMBER REALLY MATTER?
HOW CAN WE GET THE BEST OUTCOMES FROM CORD BLOOD STEM CELL TRANSPLANTATION IN SEVERE THALASSEMIC PATIENTS: WHEN DOES THE CELL NUMBER REALLY MATTER? Kleebsabai Sanpakit, 1 Bunchoo Pongtanakul, 1 Nattee
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationWhich is the best treatment for relapsed APL?
Which is the best treatment for relapsed APL? 7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, 2017 Eva Lengfelder Department of Hematology and Oncology University Hospital
More informationanemias: the current situation
Bone Marrow transplantation in rare anemias: the current situation Dr. Daria Pagliara, MD Pediatric Onco Haematology Department Ospedale Pediatrico Bambino Gesù, Rome 4th European Symposium on Rare Anaemias
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationDisclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017
2017 Updates: Management of Aplastic Anemia and Congenital Marrow Failure Sachit Patel, MD Department of Pediatrics Division of Hematology-Oncology Blood and Marrow Transplantation Disclosers None 1 Objectives:
More information21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com
Transplant Webinar Series: Ep. 6 Donor Selection for Haematopoietic Stem Cell Transplantation Future Webinars The Role of NGS in the Transplant Setting Featuring Dr Sujatha Krishnakumar Sirona Genomics,
More informationHaploidente HSCT bei Sichelzellkrankheit. Selim Corbacioglu Regensburg, Germany
Haploidente HSCT bei Sichelzellkrankheit Selim Corbacioglu Regensburg, Germany Hemoglobinopathies are the largest patient population with an absolute indication for SCT 5% of the world s popula2on are
More informationSevere Chronic Neutropenia
Haematopoietic Stem Cell Transplantation Severe Chronic Neutropenia F. Fioredda Unit of Haematology Giannina Gaslini Children s Hospital No disclosures Severe Chronic Neutropenia Persistence above 6 months
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationAre We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017
Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell Ann Haight, MD 9 Sept 2017 Spoiler alert Yes (we have a cure) And No Work to do! 2 Sickle Cell Treatment Options Supportive Care
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationCord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014
Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationHematopoietic Stem Cell Transplant for Sickle Cell Anemia: The changing landscape
Hematopoietic Stem Cell Transplant for Sickle Cell Anemia: The changing landscape Adetola A. Kassim, MD, MS Associate Professor of Medicine Hematology/Stem cell Transplant Vanderbilt University Medical
More informationHormone related problems (Endocrinopathies and osteoporosis) Vincenzo de Sanctis Ferrara.
Hormone related problems (Endocrinopathies and osteoporosis) Vincenzo de Sanctis Ferrara vdesanctis@libero.it 6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS 1 st Dutch-Belgian meeting for patients and health
More informationSICKLE CELL DISEASE TO TREAT OR
SICKLE CELL DISEASE TO TREAT OR NOT TO TREAT COHEM Barcelona September 8, 2012 Sujit Sheth, M.D. Pediatric Hematology Oncology Disclosures None Outline Morbidity and mortality Definitive therapies Risk
More informationRole of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT
Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,
More informationHOT TOPIC: Matched Related Donor Hematopoietic Stem Cell Transplant for Children with Sickle Cell Disease
November 20, 208 HOT TOPIC: Matched Related Donor Hematopoietic Stem Cell Transplant for Children with Sickle Cell Disease Patricia Kavanagh, MD Associate Professor of Pediatrics Boston University/Boston
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationNew trends in donor selection in Europe: "best match" versus haploidentical. Prof Jakob R Passweg
New trends in donor selection in Europe: "best match" versus haploidentical Prof Jakob R Passweg HSCT change in donor type: 1990-2015 9000 H S C T 8000 7000 6000 5000 4000 HLA identical sibling/twin Haplo-identical
More informationInfective hepatic complications in HSCT patients. Simone Cesaro. Pediatric Hematology Oncology Verona, Italy. Session II: organ specific complications
Session II: organ specific complications Infective hepatic complications in HSCT patients Simone Cesaro Pediatric Hematology Oncology Verona, Italy simone.cesaro@ospedaleuniverona.it Liver complications
More informationBone Marrow Transplantation in Thalassemia (Part 1)
IJMS Vol 34, No 1, March 2009 Review Article Bone Marrow Transplantation in Thalassemia (Part 1) Maryam Zakerinia Department of Internal Medicine, BMT Unit, Hematology Research Center, and Organ Transplant
More informationCell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation June 2016
Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders Company Presentation June 2016 Disclaimer These slides and the accompanying oral presentation contain
More informationShould patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy?
Should patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy? Pierre Fenaux Cohem 2012 Barcelona Should patients with higher risk MDS (or AML
More informationHematopoetic Stem Cell Therapies in TURKIYE
Hematopoetic Stem Cell Therapies in TURKIYE World Location of transplant centers participating in CIBMTR (2010) Dr. Mustafa ÇETİN Mustafa CETIN, M.D. Erciyes University Medical Faculty Kayseri-TURKIYE
More informationoptions in Myeloablative HSCT
Should Busilvex we use AlloSCT in AML options in Myeloablative HSCT Reduced Intensity or Myeloablative preparative protocols? Moderator: Andrea Bacigalupo Reduced Intensity: Arnon Nagler Myeloablative:
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationHematopoietic stem cell transplantation for sickle cell disease. Hazza Al-zahrani KFSHRC-Riyadh
Hematopoietic stem cell transplantation for sickle cell disease Hazza Al-zahrani KFSHRC-Riyadh SCD major Health Burden in KSA endemic in southern and eastern prevalence remains higher than that in other
More informationPediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center
Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationIl Trapianto da donatore MUD. Alessandro Rambaldi
Il Trapianto da donatore MUD Alessandro Rambaldi Overview Comparison of outcomes of allo- HSCT from matched related and unrelated donors. We need evidence based results! Is the Dme needed to find an unrelated
More informationRelated haploidentical donors versus matched unrelated donors
Related haploidentical donors versus matched unrelated donors Bronwen Shaw, MD PhD Professor of Medicine, MCW Senior Scientific Director, CIBMTR Definition Matched Unrelated donor Refers to HLA matching
More information"Chemotherapy based stem cell mobilization: pro and con"
"Chemotherapy based stem cell mobilization: pro and con" Mohamad MOHTY Clinical Hematology and Cellular Therapy Dpt. Sorbonne Université Hôpital Saint Antoine Paris, France Disclosures Sponsorship or research
More informationStem Cell Transplantation
Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results
More informationTHE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore
THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationPost Transplant Management for Sickle Cell. Title
Post Transplant Management for Sickle Cell Title Kimberly Kasow, DO October 14, 2016 Thank you for this opportunity to present this information I have no financial interests to disclose. Goal of Transplant
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationSylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.
Bone Marrow Research Volume 2012, Article ID 873695, 5 pages doi:10.1155/2012/873695 Clinical Study Both Optimal Matching and Procedure Duration Influence Survival of Patients after Unrelated Donor Hematopoietic
More informationOutcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched. unrelated donors
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related or matched unrelated donors Immunobiology Working Committee PIs: Peter Shaw and
More informationSickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?
Sickle Cell Diseasechronic illness or curable disease? Gregory M.T. Guilcher MD, FRCPC, FAAP Objectives To review the general principles of hematopoietic stem cell transplantation (HSCT), including risks
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationCARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center
CARs vs. BiTE in ALL David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center Disclosure Information David L Porter Speaker and members of study
More informationLONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS
LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS Farid Boulad, Susan E Prockop, Praveen Anur, Danielle
More informationImmunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience
36 supplement to Journal of the association of physicians of india Published on 1st of every month 1st march, 2015 Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationA comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
Piemontese et al. Journal of Hematology & Oncology (2017) 10:24 DOI 10.1186/s13045-017-0394-2 RESEARCH A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated
More informationLatest results of sibling HSCT in acquired AA. Jakob R Passweg
Latest results of sibling HSCT in acquired AA Jakob R Passweg Impact on Outcome: Patient Age, Disease Severity Title: Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and
More informationTransplants for MPD and MDS
Transplants for MPD and MDS The question is really who to transplant, with what and when. Focus on myelofibrosis Jeff Szer Royal Melbourne Hospital Myelodysplasia Little needs to be said Despite new therapies
More informationOutcomes of Transplantation with Related- and Unrelated-Donor Stem Cells in Children with Severe Thalassemia
Biology of Blood and Marrow Transplantation 12:683-687 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1206-0011$32.00/0 doi:10.1016/j.bbmt.2006.02.008 Outcomes of Transplantation
More informationClinical Policy Title: Hematopoietic stem cell transplant for thalassemia major and sickle cell disease
Clinical Policy Title: Hematopoietic stem cell transplant for thalassemia major and sickle cell disease Clinical Policy Number: 05.03.04 Effective Date: February 1, 2017 Initial Review Date: January 18,
More informationBlood and Marrow Transplantation for Haemoglobinopathies. Dr Josu de la Fuente St. Mary s Hospital London
Blood and Marrow Transplantation for Haemoglobinopathies Dr Josu de la Fuente St. Mary s Hospital London Aim: Stem Cell Transplanta.on 1. Eradicate of disease = achieve myeloabla8on 2. Avoid rejec8on
More informationMATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH
MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH TEJASWINI M. DHAWALE, M.D. HEME FELLOWS CONFERENCE NOVEMBER 08, 2013 CASE PRESENTATION 51 yo M with history of MDS (unilinear
More informationHuman Leukocyte Antigens and donor selection
Human Leukocyte Antigens and donor selection Duangtawan Thammanichanond, MD. PhD. Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University Outline
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationClinical Policy Title: Hematopoietic stem cell transplant for thalassemia major and sickle cell disease
Clinical Policy Title: Hematopoietic stem cell transplant for thalassemia major and sickle cell disease Clinical Policy Number: 05.03.04 Effective Date: February 1, 2017 Initial Review Date: January 18,
More informationPERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey
PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey Joint Educational Meeting of the EBMT Severe Aplastic Anaemia, Late Effects and Autoimmune Diseases Working Parties
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationBusulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate
Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Donald Hutcherson, RPh Clinical Pharmacy Specialist BMT Emory University Hospital/Winship Cancer Institute
More informationADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES
ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES Corey Cutler, MD MPH FRCPC Associate Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute, Boston, MA HCT Outcomes - MDS 2001-2011
More informationBlood and Marrow Transplant (BMT) for Sickle Cell Disease
Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook
More informationHAEMATOPOIETIC STEM CELL TRANSPLANTATION
PRIMARY IMMUNODEFICIENCIES HAEMATOPOIETIC STEM CELL TRANSPLANTATION HAEMATOPOIETIC STEM CELL TRANSPLANTATION 1 PRIMARY IMMUNODEFICIENCIES KEY ABBREVIATIONS CID GvHD HSCT IPOPI PID SCID BMT HSC Combined
More informationCost issues. BLOOD AND CANCER SECRETS May, 2014 Vol. 2, N1
Review article A GLOBAL RESPONSE TO A GLOBAL PROBLEM: THE RISING BURDEN OF HEMOGLOBINOPATHIES Lawrence Faulkner, MD Cure2Children Foundation, Florence, Italy lawrence.faulkner@cure2children.org Introduction
More informationHSCT for Thalassemia Major. 1. Have Transfusion. 2. Half transplantation. 1. Have transplantation. 2. Have transplantation
HSCT for Thalassemia Major 1. Have Transfusion or 1. Have transplantation or 2. Half transplantation 2. Have transplantation Said Yousuf Mohamed, Professor of Internal Medicine, H.O.T Ain Shams University
More informationCLINICAL RESEARCH. KEY WORDS: Hemoglobinopathies, Conditioning regimen, Regimen-related toxicity
CLINICAL RESEARCH Unpredictability of Intravenous Busulfan Pharmacokinetics in Children Undergoing Hematopoietic Stem Cell Transplantation for Advanced Beta Thalassemia: Limited Toxicity with a Dose-Adjustment
More informationClinical Policy: Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-thalassemia
Clinical Policy: Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-thalassemia Reference Number: CP.MP.108 Effective Date: 03/16 Last Review Date: 03/17 See Important Reminder at the
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More information